Lenvima Approval Status Worldwide (Country/ Region) November, 2018

Thyroid cancer Australia Jan-2016 Ireland May-2015 Russia Dec-2015 Austria May-2015 Israel Jan-2016 Singapore Apr-2016 Belgium May-2015 Italy May-2015 Slovakia May-2015 Brazil Aug-2016 Japan Mar-2015 Slovenia May-2015 Bulgaria May-2015 Kuwait May-2016 South Korea Oct-2015 Canada Dec-2015 Latvia May-2015 Spain May-2015 Croatia May-2015 Lebanon Nov-2016 Sweden May-2015 Cyprus May-2015 Liechtenstein May-2015 Switzerland Aug-2015 Czech Republic May-2015 Lithuania May-2015 Taiwan Sep-2016 Denmark May-2015 Luxembourg May-2015 Thailand Mar-2016 Estonia May-2015 Macau Sep-2015 UAE Feb-2017 Finland May-2015 Malaysia Nov-2016 UK May-2015 France 28-May-15 Malta May-2015 US Feb-2015 Germany May-2015 Mexico May-2016 Greece May-2015 Netherlands May-2015 Hong Kong May-2016 Norway May-2015 Hungary May-2015 Philippines Dec-2016 Iceland May-2015 Poland May-2015 India Jan-2017 Portugal May-2015 Indonesia Jul-2018 Romania May-2015

Note: The purpose of this document is to indicate that Eisai seeks to expand access to its products to patients in the world. Specific indication may vary in each country/region. Approval does not guarantee product availability. Lenvima Approval Status Worldwide (Country/ Region) November, 2018

2nd line renal cell carcinoma Australia Jul-2017 Latvia Aug-2016 Sweden Aug-2016 Austria Aug-2016 Lebanon May-2017 Switzerland Aug-2017 Belgium Aug-2016 Liechtenstein Aug-2016 Taiwan Jul-2017 Bulgaria Aug-2016 Lithuania Aug-2016 Thailand Mar-2018 Canada Sep-2017 Luxembourg Aug-2016 UK Aug-2018 Croatia Aug-2016 Macau Jul-2018 US May-2016 Cyprus Aug-2016 Malaysia Oct-2018 Czech Republic Aug-2016 Malta Aug-2016 Denmark Aug-2016 Mexico Jan-2018 Estonia Aug-2016 Netherlands Aug-2016 Finland Aug-2016 Norway Aug-2016 France Aug-2016 Philippines Dec-2016 Germany Aug-2016 Poland Aug-2016 Greece Aug-2016 Portugal Aug-2016 Hong Kong Nov-2017 Romania Aug-2016 Hungary Aug-2016 Russia Sep-2016 Iceland Aug-2016 Singapore May-2017 Ireland Aug-2016 Slovakia Aug-2016 Israel Dec-2016 Slovenia Aug-2016 Italy Aug-2016 Spain Aug-2016 In Europe, lenvatinib is approved under the brand name Kisplyx® for treatment of renal cell carcinoma

Note: The purpose of this document is to indicate that Eisai seeks to expand access to its products to patients in the world. Specific indication may vary in each country/region. Approval does not guarantee product availability. Lenvima Approval Status Worldwide (Country/ Region) November, 2018

Hepatocellular carcinoma Australia Sep-2018 Liechtenstein Aug-2018 Austria Aug-2018 Lithuania Aug-2018 Belgium Aug-2018 Luxembourg Aug-2018 Bulgaria Aug-2018 Malta Aug-2018 China Sep-2018 Netherlands Aug-2018 Croatia Aug-2018 Norway Aug-2018 Cyprus Aug-2018 Philippines Oct-2018 Czech Republic Aug-2018 Poland Aug-2018 Denmark Aug-2018 Portugal Aug-2018 Estonia Aug-2018 Romania Aug-2018 Finland Aug-2018 Slovakia Aug-2018 France Aug-2018 Slovenia Aug-2018 Germany Aug-2018 South Korea Aug-2018 Greece Aug-2018 Spain Aug-2018 Hungary Aug-2018 Sweden Aug-2018 Iceland Aug-2018 Switzerland Oct-2018 Ireland Aug-2018 Taiwan Nov-2018 Italy Aug-2018 UK Aug-2018 Japan Mar-2018 US Aug-2018 Latvia Aug-2018

Note: The purpose of this document is to indicate that Eisai seeks to expand access to its products to patients in the world. Specific indication may vary in each country/region. Approval does not guarantee product availability.